Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internat…
Biotechnology
US, Novato [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Ultragenyx Pharmaceutical Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2016 | -3.9600 | -6.142 | 0 | 0.25 | -145 | -236 | -146 | -234 | -147 | -238 | 33 | 0.22 |
| 2017 | -6.2100 | -7.278 | 0.13 | 0.61 | -245 | -309 | -248 | -327 | -248 | -337 | 64 | 0.53 |
| 2018 | -7.1200 | -4.172 | 2 | 49 | -302 | -115 | -328 | -69 | -328 | -777 | 99 | 42 |
| 2019 | -3.9700 | -6.938 | 51 | 100 | -197 | -379 | -541 | -367 | -371 | -400 | 127 | 87 |
| 2020 | -7.1200 | -3.794 | 103 | 250 | -402 | -176 | -411 | -101 | -424 | -515 | 161 | 216 |
| 2021 | -3.0700 | -6.254 | 271 | 351 | -186 | -396 | -322 | -355 | -330 | -344 | 182 | 198 |
| 2022 | -6.7000 | -9.922 | 351 | 361 | -454 | -413 | -381 | -375 | -381 | -399 | 219 | 215 |
| 2023 | -10.1200 | -8.372 | 363 | 428 | -707 | -585 | -639 | -431 | -648 | -456 | 278 | 244 |
| 2024 | -8.2500 | -6.400 | 434 | 536 | -606 | -470 | -516 | -536 | -569 | -536 | 309 | 465 |
| 2025 | - | -5.277 | - | 628 | - | -393 | - | -628 | - | -628 | - | 544 |
| 2026 | - | 2.F10X/td> | - | 2.F10X/td> | - | 2.F10X/td> | - | 2.F101/td> | - | 2.F101 | - | 2.F101 |
| 2027 | - | 1.F11X/td> | - | 1.F11X/td> | - | 1.F11X/td> | - | 1.F111/td> | - | 1.F111 | - | 1.F111 |
| 2028 | - | 0.F12X/td> | - | 0.F12X/td> | - | 0.F12X/td> | - | 0.F121/td> | - | 0.F121 | - | 0.F121 |